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ABSTRACT 29 
Antioxidant and angiotensin I-converting enzyme (ACE)-inhibitory activities of 30 
sardinelle (Sardinella aurita) protein hydrolysates (SPHs) obtained by fermentation with 31 
Bacillus subtilis A26 (SPH-A26) and Bacillus amyloliquefaciens An6 (SPH-An6) were 32 
investigated. Both hydrolysates showed dose-dependent antioxidant activities evaluated using 33 
various in vitro antioxidant assays. Further, they were found to exhibit ACE-inhibitory 34 
activity. Peptides from SPH-A26 and SPH-An6 were analyzed by nESI-LC–MS/MS and 35 
approximately 800 peptides were identified. Identified peptides derived mainly from myosin 36 
(43% and 31% in SPH-An6 and SPH-A26, respectively). Several peptides identified in both 37 
hydrolysates were found to share sequences with previously identified antioxidant and ACE-38 
inhibitory peptides based on Biopep database. Some of these peptides were selected for 39 
synthesis and their biological activities were evaluated. Among the synthesized peptides, 40 
NVPVYEGY and ITALAPSTM were found to be the most effective ACE-inhibitors with 41 
IC50 values of 0.21 and 0.23 mM, respectively. On the other hand, NVPVYEGY, which 42 
exhibited the highest ACE-inhibitory activity, showed the highest reducing power and peroxyl 43 
radical scavenging activities, followed by SLEAQAEKY and GTEDELDKY.  The results of 44 
this study suggest that fermented sardinelle protein hydrolysates are a good source of natural 45 
antioxidant peptides and could have the potential to act as hypotensive nutraceutical 46 
ingredients. 47 
 48 
 49 
Keywords : Sardinella aurita; Fermentation; Protein hydrolysates; Antioxidant activity; 50 
ACE-inhibitory activity; Peptidomic analysis. 51 
 52 
 53 
3 
 
1. Introduction 54 
Elevated blood pressure is one of the major independent risk factors for cardiovascular 55 
disease (Harris, Cook, Kannel, Schatzkin, & Goldman, 1985). Angiotensin I-converting 56 
enzyme (ACE, peptidyldipeptide hydrolase) plays an important role in the renin-angiotensin 57 
system, which regulates human blood pressure and fluid homeostasis. ACE converts the 58 
inactive form of decapeptide angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) into a 59 
powerful vasoconstrictor, the octapeptide angiotensin II by removing the C-terminal dipeptide 60 
His-Leu (Lavoie & Sigmund, 2003). In addition, ACE inactivates the vasodilator bradykinin 61 
(Lavoie & Sigmund, 2003). Therefore, the inhibition of ACE is considered to be a useful 62 
approach in the treatment of hypertension. 63 
Specific inhibitors of ACE, such as captopril, lisinopril and enalapril, have been shown to 64 
be useful as antihypertensive drugs (Salvetti, 1990). However, these ACE-inhibitory drugs 65 
have some undesirable side effects such as cough, lost of taste, renal impairment and 66 
angioneurotic edema (Cooper et al., 2006). Thus, the search for natural safe and more 67 
effective ACE-inhibitory agents as alternative to synthetic drugs is necessary for the 68 
prevention and treatment of hypertension. 69 
As a result, the interest in identifying foods as potential natural sources of ACE-70 
inhibitory peptides has increased (Houston, 2005). In fact, several ACE-inhibitory peptides 71 
have been isolated from various food sources such as Spanish dry-cured ham (Escudero et al., 72 
2013), soya milk (Tomatsu, Shimakage, Shinbo, Yamada, & Takahashi, 2013), goby muscle 73 
protein (Nasri et al., 2013), jellyfish (Liu et al., 2013), smooth hound viscera (Abdelhedi et 74 
al., 2016) and thornback ray muscle (Lassoued et al., 2015). 75 
Organisms are constantly exposed to various forms of reactive oxygen species that lead to 76 
the oxidation of proteins, nucleic acids and lipids. In addition, deterioration of many foods 77 
occur due to the oxidation of lipids and formation of secondary lipid peroxidation products. 78 
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Therefore, a great interest has been developed to identify new antioxidant compounds from 79 
different sources to overcome problems related to lipid peroxidation. Different recent studies 80 
reported that peptides derived from certain protein hydrolysates, and especially from marine 81 
sources, could act as potential antioxidants (Lassoued et al., 2015, Kleekayai et al., 2015, 82 
Sudhakar, & Abdul Nazeer, 2015). 83 
According to literature, the most widely used method for the production of protein 84 
hydrolysates is the controlled enzymatic digestion. Few studies have been conducted on the 85 
generation of biologically active peptides using microbial fermentation. In a previous work, 86 
we reported the production of antioxidant and antibacterial protein hydrolysates from fish 87 
meat fermented by Bacillus subtilis A26 (Jemil et al., 2014) and Bacillus amyloliquefaciens 88 
An6 and their potential use in vivo for the treatment of hyperlipidemia in high-fat fed wistar 89 
rats (Jemil et al., 2016). Fakhfakh, Ktari, Siala, & Nasri (2013) reported the production of 90 
protein hydrolysates with high antioxidant potential from wool-waste by fermentation with a 91 
new keratinolytic bacterium, Bacillus pumilus A1. In another study, Torino et al. (2013) 92 
reported that solid-state fermented lentils by Bacillus subtilis showed ACE-inhibitory activity. 93 
More recently, Chakka, Elias, Jini, Sakhare, & Bhaskar (2015) reported the production of 94 
chicken liver protein hydrolysates by fermentation using the lactic acid bacteria Pediococcus 95 
acidilactici NCIM5368. 96 
Therefore, the aim of this study was to investigate the antioxidant and ACE-inhibitory 97 
activities of fermented sardinelle protein hydrolysates and to identify potent bioactive peptide 98 
sequences by LC-MS/MS. A peptidomic analysis based on Biopep database was done to 99 
identify potential biopeptides that were synthesized and tested in vitro. 100 
 101 
2. Materials and methods 102 
2.1.  Reagents 103 
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1,1-diphenyl-2-picrylhydrazyl (DPPH) and butylated hydroxyanisole (BHA) were 104 
purchased from Sigma Chemical Co. (St. Louis, MO, USA). ACE from rabbit lung and ACE 105 
synthetic substrate o-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline (Abz-Gly-Phe-106 
(NO2)-Pro) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Acetonitrile, 107 
methanol, and ethanol HPLC grade were from Scharlau (Scharlab SL, Barcelona, Spain). All 108 
solutions were freshly prepared in bi-distilled water obtained from a Culligan system; the 109 
resistivity was approximately 18 MΩ*cm. 110 
 111 
2.2.Material 112 
Sardinelle (Sardinella aurita) was freshly purchased from the local fish market of Sfax 113 
City, Tunisia. The sample was packed in polyethylene bags, placed in ice with a sample/ice 114 
ratio of approximately 1:3 (w/w) and transported to the laboratory within 30 min. Muscles 115 
were separated and rinsed with cold distilled water to remove salts and other contaminants. 116 
 117 
2.3.Preparation of undigested sardinelle proteins (USP) 118 
Raw muscle from sardinelle (500 g) was cooked for 20 min at 100 °C in 1000 mL bi-119 
distilled water. The bones were removed from cooked fish and fillets were collected and dried 120 
at 80 °C for 18 h. The dried fish preparation was minced to obtain USP.  121 
 122 
2.4. Production of fermented sardinelle protein hydrolysates 123 
B. subtilis A26 (CTM 50700) (Agrebi et al., 2009) and B. amyloliquefaciens An6 (Agrebi 124 
et al., 2010), known to produce several proteolytic enzymes, were employed to obtain protein 125 
hydrolysates through fermentation of sardinelle proteins. Inoculums were grown in medium 126 
containing only powdered sardinelle meat (30 g/l; pH 8.0) as a unique carbon and nitrogen 127 
source (Jemil et al., 2014). Media were autoclaved at 121 °C for 20 min. Cultivations were 128 
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conducted in 1000 mL Erlenmeyer flasks, containing 100 mL of culture medium. Incubations 129 
were carried out in a shaking incubator (Technico Ltd, Chennai, India) at 200 rpm for 24 h at 130 
37 °C. The growth of the microorganisms was estimated by the determination of colony 131 
forming units per milliliter. Cultures were then centrifuged at 8500×g for 30 min at 4 °C. 132 
Resulted cell-free supernatants containing SPHs were freeze dried (Bioblock Scientific Christ 133 
ALPHA 1-2, IllKrich-Cedex, France) and stored at - 20 °C. The freeze dried powders, with a 134 
yield of 0.3 and 0.35 g of dried powder g-1 of USP, respectively, were evaluated for antioxidant 135 
and anti-ACE activities. All experiments were carried out in triplicate. 136 
 137 
2.5.  Determination of the degree of hydrolysis (DH) 138 
DH was measured using o-phthaldialdehyde (OPA) following the method referred by 139 
Nielsen, Petersen, & Dambmann (2001). An aliquot of the sample (400 μl), at a concentration 140 
of 1 mg mL-1, was added to 3 mL of OPA solution and homogenized for 5 seconds. The 141 
absorbance of mixtures was measured after 2 min at 340 nm. The same volume of distilled 142 
water instead of SPH sample was used as control. A serine standard was also prepared (0.1 143 
mg mL-1).  144 
The DH was expressed in percentage and calculated using the following formulas : 145 
 146 
 147 
 148 
 149 
 150 
 151 
 152 
where Abssample is the absorbance of SPH, Absserine is the absorbance of serine standard, 153 
Abscontrol is the absorbance of control, W is the weight in grams of SPH sample in 100 mL and 154 
P is the protein content (%) of SPH. Constants values of the number of equivalent peptide 155 
100 h DH = 
htot 
 
× 
 Serine–NH2 - β 
h = 
α 
Serine –NH2 = × 
0.9516 × 0.1 × 10 
 
W × P 
 Abssample - Abscontrol 
 Absserine - Abscontrol 
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bonds per gram of protein (htot), α and β were assumed to be 8.6 meq g-1, 1 and 0.4, 156 
respectively, since these are the recommended values for fish by Nielsen, Petersen, & 157 
Dambmann (2001). Each experiment was done in triplicate. 158 
 159 
2.6.  Chemical analysis 160 
Moisture and ash contents were determined according to the AOAC standard methods 161 
930.15 and 942.05, respectively (AOAC. 2000). Total nitrogen content of SPHs and 162 
undigested protein substrates were determined using the Kjeldahl method according to the 163 
AOAC method number 984.13 (AOAC. 2000) and the equipment of BÛCHI Digestion Unit 164 
K-424, Switzerland. Protein content was estimated by multiplying total nitrogen content by 165 
the factor of 6.25. Fat content was determined gravimetrically after Soxhlet extraction of dried 166 
samples with hexane for 2 h using heating mantle. All measurements were performed in 167 
triplicate.  168 
 169 
2.7.Determination of ACE-inhibitory activity 170 
The ACE-inhibitory activity of SPHs and synthesized peptides was measured according 171 
to Sentandreu & Toldrá (2006), based on the hydrolysis of the fluorescent substrate o-172 
aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline (Abz-Gly-Phe-(NO2)-Pro). A sample 173 
solution (50 μL) was mixed with 50 μL of 150 mM Tris-base buffer (pH 8.3) containing 3 Mu 174 
mL-1 of ACE, and incubated for 10 min at 37 °C. Then, 200 μL of 150 mM Tris–HCl buffer 175 
(pH 8.3) containing 1.125 M NaCl and 10 mM Abz-Gly-Phe-(NO2)-Pro are added and 176 
incubated at 37 °C for 45 min. The released o-aminobenzoylglycine (Abz-Gly) was measured 177 
at 355 and 405 nm as excitation and emission wavelengths, respectively. ACE inhibition of 178 
SPHs and the most active synthesized peptides was expressed as a percentage and the IC50 as 179 
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the amount of peptide required to inihibit 50% of ACE activity. Captopril was used as 180 
positive control. The test was carried out in triplicate. 181 
 182 
2.8.Antioxidant activities 183 
2.8.1. DPPH radical-scavenging assay 184 
The DPPH radical-scavenging activity of the hydrolysates was determined as described 185 
by Bersuder, Hole, & Smith (1998), with minor changes. A 96 well microplate reader (Opsys 186 
MR™, Dynex Technologies, VA, USA) with detection at 490 nm was used to carry out the 187 
assay. A volume of 100 μL of each sample was added to 100 μL of 99.5% ethanol and 25 µL 188 
of 0.02% DPPH in 99.5%. After 60 min in the dark, the absorption was measured at 490 nm. 189 
The control was conducted in the same manner, except that distilled water was used instead of 190 
sample. 191 
The DPPH radical-scavenging activity was calculated as follows:  192 
 193 
 194 
where Asample is the absorbance of the solution containing the sample and Acontrol is the 195 
absorbance of the control reaction. BHA was used as positive control. The test was carried out 196 
in triplicate and the results were mean values. 197 
 198 
2.8.2.  Reducing power assay  199 
The ability of SPHs and synthesized peptides to reduce Fe3+ was determined according 200 
to the method of Yildirim, Mavi, & Kara (2001). The sample (1 mL) was mixed with 2.5 mL 201 
of 0.2 M phosphate buffer (pH 6.6) and 2.5 mL of 1% (w/v) potassium ferricyanide solution 202 
and incubated for 30 min at 50 °C. Thereafter, 2.5 mL of 10% (w/v) trichloroacetic acid was 203 
added and the reaction mixture was then centrifuged for 10 min at 10,000×g. The supernatant 204 
100 × Acontrol - Asample DPPH radical-scavenging activity (%) = 
Acontrol 
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solution (2.5 mL) was mixed with 2.5 mL of distilled water and 0.5 mL of 1% (w/v) ferric 205 
chloride and the absorbance was measured at 690 nm after 10 min of reaction time. 206 
Alternatively, the assay can be miniaturized and carried out in 96-well plate, where volumes 207 
of reagents were proportionally reduced. The absorbance of each well was read using a 208 
microplate reader (Opsys MR™ 96-well microplate reader, Dynex Technologies, VA, USA). 209 
Increases in absorbance values indicate higher reducing power capacity (Suryakanth et al., 210 
2012). BHA was used as positive control. The test was carried out in triplicate. 211 
 212 
2.8.3.  β-carotene bleaching assay 213 
The ability of SPHs and synthesized peptides to prevent β-carotene bleaching was 214 
assessed as described by Koleva, Van Beek, Linssen, De Groot, & Evstatieva (2002). A stock 215 
solution of β-carotene/linoleic acid mixture was prepared by dissolving 0.5 mg of β-carotene, 216 
20 µL of linoleic acid and 200 µL of Tween 80 in 1 mL of chloroform. The chloroform was 217 
completely evaporated under vacuum in a rotatory evaporator at 40 °C, then 100 mL of 218 
double-distilled water were added, and the resulting mixture was vigorously stirred. The 219 
obtained emulsion obtained was freshly prepared before each experiment. Aliquots (2.5 mL) 220 
of the β-carotene/linoleic acid emulsion were transferred to test tubes containing 0.5 mL of 221 
SPHs samples. After one hour incubation at 50 °C, the absorbance of each sample was 222 
measured at 470 nm. Regarding synthesized peptides, the assay was miniaturized and carried 223 
out in 96-well plate, where all volumes were proportionally reduced. The absorbance of each 224 
well was read using a 96 well microplate reader (Opsys MR™ 96-well microplate reader, 225 
Dynex Technologies, VA, USA) with detection at 450 nm. A total of 200 µL of the β-226 
carotene/linoleic acid mixture were added to each well containing 50 µL of each synthesized 227 
peptide. After one hour of incubation at 50 °C, the absorbance of each sample was measured 228 
at 470 nm. BHA was used as positive control. The test was carried out in triplicate.  229 
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2.8.4.  Determination of metal chelating activity (ferrozine assay) 230 
The chelating activity of the SPHs for Fe2+ was measured according to the method 231 
described by Dinis, Maderia, & Almeida (1994). Thus, a total of 150 µL of distilled water and 232 
25 µL of FeCl2 (2 mM) were added to 50 µL of hydrolysate, followed by the addition of 100 233 
µL of ferrozine (5 mM) after 5 min. After a-10 min incubation at room temperature, the 234 
absorbance of the Fe2+-ferrozine complex with red or violet color was measured at 562 nm. 235 
The chelating activity of the antioxidant for Fe2+ was calculated according to the following 236 
formula: 237 
 238 
where Acontrol is the absorbance of the control (without sample), Ablank is the absorbance of the 239 
blank (without ferrozine) and Asample is the absorbance of SPHs. EDTA was used as positive 240 
control. All determinations were performed in triplicate. 241 
 242 
2.8.5.  Oxygen radical absorbance capacity (ORAC) assay 243 
ORAC of hydrolysates and synthesized peptides was carried out according to the 244 
procedure reported by Dávalos, Gómez-Cordovés, Bartolomé, & (2004) with minor 245 
modifications. The ORAC assay was measured using a Fluoroskan Ascent FL 246 
(Thermo Electron Corporation, Waltham, MA). Briefly, the microplate equipped with an 247 
incubator and wavelength-adjustable fluorescence filters was used to monitor for the reaction. 248 
The temperature of the incubator was set at 37 °C, and fluorescence filters with excitation 249 
wavelength of 485 nm and emission wavelength of 538 nm were used. AAPH was used as 250 
peroxyl generator and Trolox was used as antioxidant standard. The plate reader was 251 
programmed to record the fluorescence of fluorescein on every cycle. Kinetic reading was 252 
recorded for 100 cycles with 60 s per cycle setting. Trolox standards were prepared with 253 
phosphate buffered saline (PBS) (75 mM, pH 7.4), which was used as blank. The samples 254 
100 × (Acontrol + Ablank − Asample) Ferrous ion-chelating activity (%) = 
Acontrol 
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were diluted with PBS (75 mM, pH 7.4) to the proper concentration range for fitting the 255 
linearity range of the standard curve. After loading 140 μL of sample, standard and blank, and 256 
70 μL of the fluorescein solution (200 nM) into appointed wells according to the layout, the 257 
microplate was incubated for 15 min in the plate reader, then 70 μL of peroxyl generator 258 
AAPH (80 mM) was added to initiate the oxidation reaction. The final ORAC values were 259 
calculated using a linear equation between the Trolox standards or sample concentration and 260 
net area under the fluorescence decay curve. The ORAC value was expressed as micromolar 261 
of Trolox equivalent (µM TE) using the calibration curve of Trolox. All determinations were 262 
performed in triplicate. 263 
 264 
2.9. Identification of peptides using nESI-LC–MS/MS 265 
Peptide identification was done using a nano-liquid chromatography system (Eksigent 266 
of AB Sciex, CA) coupled to a quadrupole-time-of-flight (Q-ToF) system (TripleTOF® 267 
5600+, AB Sciex Instruments, Framingham, MA) equipped with a nano-electrospray 268 
ionization source (nano-ESI). Systems parameters were adjusted as previously published in 269 
Mora, Escudero, Aristoy, & Toldrá (2015). 270 
Regarding the spectra analysis, peak list generation and database search for the 271 
identification of the peptides were done using Mascot Distiller v2.4.2.0 software (Matrix 272 
Science, Inc., Boston, MA).  NCBInr protein database was used to identify the peptides with a 273 
significance threshold p < 0.05 and a FDR (False Discovery Rate) of 1.5%. The tolerance on 274 
the mass measurement was 100 ppm in MS mode and 0.3 Da in MS/MS ions. BIOPEP 275 
(http://www.uwm.edu.pl/biochemia/index.php/pl/biopep) databases were used to search of 276 
similar sequences previously described as ACE-inhibitory or antioxidant. 277 
 278 
2.10. Peptide synthesis 279 
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The most promising sequences of identified peptides were synthesized by GenScript 280 
Corporation (Piscataway, NJ, USA) in order to assess their in vitro activities. The synthesized 281 
peptides and their purity were certified by analytical LC–MS. 282 
 283 
2.11. Statistical analyses 284 
Statistical analyses were performed with Stratgraphics ver. 5.1, professional edition 285 
(Manugistics Corp., USA) using ANOVA analysis. Differences were considered significant at 286 
p< 0.05. 287 
 288 
3. Results and discussion 289 
3.1. Preparation and characterization of fermented sardinelle protein hydrolysates  290 
In this study, the fermentation of sardinelle muscle proteins was carried out during 24 h. 291 
The extent of protein hydrolysis during fermentation by B. subtilis (A26) and B. 292 
amyloliquefaciens (An6) strains was measured by assessing the degree of hydrolysis and the 293 
proteolytic activity. The findings revealed that An6 strain showed a higher hydrolytic activity 294 
(DH = 24.3%) in comparison with SPH-A26 that was 21.56%. The proteolytic activity in 295 
cultures of A26 and An6, using sardinelle proteins as substrate, were estimated at 400 U mL-1 296 
and 250 U mL-1, respectively. The high DH values obtained were mainly due to the 297 
production of several proteases by the two strains. The difference in DH values could be 298 
mainly due to the difference in the specificity of enzymes produced by the proteolytic bacteria 299 
used and may reflect the generation of small sized bioactive peptides in the hydrolysate 300 
mixtures. It has been reported that high DH values are suitable for the generation of 301 
antioxidant and ACE-inhibitory peptides (Nasri et al., 2014). 302 
The chemical composition of freeze dried SPHs was determined and compared to that 303 
of undigested sardinelle proteins. The proximate composition of dried SMF showed that it had 304 
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high protein content (76.43% of dry matter basis). In fermented SPHs, protein content was 305 
about 75%. The lipid level in the hydrolysates was about 0.7%, which is lower than that of 306 
USP (15.65%). SPH-A26 and SPH-An6 had high ash content, 9.8% and 9%, respectively. 307 
 308 
3.2.ACE-inhibitory activity of SPHs 309 
The ACE-inhibitory activity of SPH-A26 and SPH-An6 was investigated at different 310 
concentrations. As reported in Fig. 1, both fermented hydrolysates exhibited high ACE-311 
inhibitory activity in a dose dependent manner reaching 75.7% ± 0.66 and 79.5% ± 0.33 at 0.6 312 
mg mL-1 for SPH-A26 and SPH-An6, respectively. The concentration of hydrolysates 313 
required to inhibit 50% of the ACE activity (IC50 values) was determined and SPH-An6 314 
showed an IC50 value of 0.21 ± 0.001 mg mL-1, whereas SPH-A26 showed an IC50 value of 315 
0.26 ± 0.006 mg mL-1. It is interesting to note that SPH-An6, which showed the highest DH 316 
(DH= 24.3%), exhibited the lowest IC50 value. The IC50 values of the two hydrolysates were 317 
lower than those of salmon skin collagen hydrolysate (1.165 ± 0.087 mg mL-1) obtained by 318 
treatment with alcalase and papain (Gu, Li, Liu, Yi, & Cai, 2011) and goby muscle 319 
hydrolysates prepared with different proteases (1.36–3.33 mg mL-1) (Nasri et al., 2013). In 320 
another study, Alemán et al. (2011) reported IC50 values between 0.34 and 1.6 mg mL-1 for 321 
squid gelatine hydrolysates prepared by several commercial proteases. However, both IC50 322 
values were nearly similar to that of liquid state lentils fermented by Lactobacillus plantarum 323 
(IC50= 0.20 mg mL-1) (Torino et al., 2013). 324 
No ACE-inhibitory activity was detected with USP. Therefore, the results indicated that 325 
ACE-inhibitory peptides are encrypted within the sardinelle proteins and could be released 326 
through the action of proteolytic enzymes derived from proteolytic bacteria during 327 
fermentation.  328 
 329 
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3.3. Antioxidant activities 330 
3.3.1.  DPPH free radical-scavenging activity 331 
DPPH is a stable free radical that shows maximum absorbance at 517 nm. When DPPH 332 
radicals encounter a hydrogen-donating substrate such as an antioxidant, the radicals would be 333 
scavenged and the absorbance is reduced (Shimada, Fujikawa, Yahara, & Nakamura, 1992). 334 
The decrease in absorbance is taken as a measure for radical-scavenging activity. Fig. 2a 335 
shows the DPPH radical-scavenging activity of SPHs and BHA, used as positive control, at 336 
different concentrations. The results clearly indicated that both hydrolysates were able to 337 
scavenge DPPH radical with a dose-dependent manner and SPH-An6 exhibited the highest 338 
radical-scavenging activity (70 ± 0.8% at 5 mg mL-1). The obtained results are in line with 339 
previous works reported by Morales-Medina, Tamm, Guadix, Guadix, & Drusch (2016) and 340 
Bkhairia et al. (2016) who reported that the DPPH scavenging activity increases with 341 
increasing protein hydrolysate concentrations. However, the two hydrolysates showed lower 342 
radical scavenging activity than BHA (2 mM; 92.5 ± 1.7%). The obtained results suggested 343 
that some peptides within sardinelle protein hydrolysates would be significantly strong radical 344 
scavengers. 345 
 346 
3.3.2.  Reducing power 347 
In this assay, the ability of hydrolysates to reduce Fe3+ to Fe2+ was determined. The 348 
presence of antioxidants in the protein hydrolysate results in reduction of the Fe3+/ferric 349 
cyanide complex to the ferrous form. As shown in Fig. 2b, the reducing power activity (as 350 
indicated by the absorbance at 690 nm) of both hydrolysates and BHA increased with 351 
increasing concentrations. A little difference in the reducing power activities was observed 352 
between the two hydrolysates. Nevertheless, both hydrolysates showed lower reducing power 353 
than did BHA at the same concentrations. 354 
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3.3.3.  Antioxidant activity measured by the β-carotene bleaching method 355 
The antioxidant assay using the discoloration of β-carotene is widely employed to 356 
measure the antioxidant activity of bioactive compounds, because β-carotene is extremely 357 
susceptible to free radical-mediated oxidation of linoleic acid (Kumazawa et al., 2002). In this 358 
test, β-carotene undergoes a rapid discoloration in the absence of antioxidant, which results in 359 
the reduction in absorbance of the test solution with increasing reaction time. The presence of 360 
antioxidant hinders the extent of bleaching by neutralizing the linoleic hydroperoxyl radicals 361 
formed. The antioxidant activities of SPHs measured by β-carotene bleaching are reported in 362 
Fig. 2c. The two hydrolysates inhibited the oxidation of β-carotene at different degrees and in 363 
a dose-dependent manner. SPH-An6 showed slightly higher ability to prevent bleaching of β-364 
carotene than did SPH-A26. However, the inhibition of β-carotene bleaching of both 365 
hydrolysates was lower than that obtained by BHA (92%). These results demonstrated that 366 
SPHs prevent β-carotene bleaching by potentially donating hydrogen atoms to peroxyl 367 
radicals of linoleic acid. 368 
 369 
3.3.4.  Ferrous ion-chelating activity 370 
The chelation of Fe2+ was used to determine the ability of protein hydrolysates in metal-371 
chelating activity. Ferrozine quantitatively forms complex with Fe2+ ions. In the presence of 372 
chelating agents, the complexe formation is disrupted, resulting in the decrease in colour 373 
formation (Thiansilakul, Benjakul, & Shahidi, 2007). Ferrous chelating activity of SPHs and 374 
EDTA used as reference chelating agent, at different concentrations, are shown in Fig. 2d. 375 
The results indicated that SPHs are able to chelate Fe2+ ion. In a dose-dependent manner, 376 
SPH-An6 exhibited high activity (86.85% ± 3.01 at 5 mg mL-1) than did SPH-A26 (47.62% ± 377 
2.75 at 5 mg mL-1) (p<0.05). Chelating activity of SPH-An6 was higher than Flavourzyme 378 
hydrolyzed silver carp proteins (60% at 5 mg mL-1) (Dong et al., 2008) and lower than 379 
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enzymatic sardinelle protein hydrolysates (between 54.82 and 78% at 0.25 mg mL-1) (Ben 380 
Khaled et al., 2014).  381 
Transition metals such as Fe2+ and Cu2+ can catalyse the generation of reactive oxygen 382 
species such as hydroxyradical (OH°) and superoxide anion (O2−) (Stohs & Bagchi, 1995). In 383 
fact, Fe2+ generates OH° by the Fenton reaction, when the lipid peroxidation chain reaction is 384 
accelerated. The results indicate that protein hydrolysates can exhibit, to a various extent, 385 
antioxidant ability by capturing ferrous ion or other ions. Therefore, chelation of metal ions 386 
by peptides in hydrolysates would retard the oxidative reaction (Klompong, Benjakul, 387 
Kantachote, Hayes, & Shahidi, 2008).  388 
 389 
3.3.5. ORAC assay 390 
The ORAC assay has been used to study the antioxidant capacity of many compounds 391 
and food samples (Wu et al., 2004; Xu, Yuan, & Chang, 2007). ORAC values of SPHs at 392 
different concentrations are presented in Fig. 2e. The results indicated that SPH-An6, with the 393 
highest DH value, has a higher oxygen radical antioxidant capacity than SPH-A26 and that 394 
this capacity increased with increasing concentration. 395 
 396 
3.4.Identification of peptides in SPH-A26 and SPH-An6 397 
Peptides in SPH-A26 and SPH-An6 were analysed by nESI-LC–MS/MS. A total of 398 
approximately 800 peptides were identified. Fig. 3 shows the distribution in percentages of 399 
the identified peptides according to their origin proteins. Main identified peptides derived 400 
from myosin (31% in SPH-A26 and 43% in SPH-An6), followed by actin (12% and 17% in 401 
SPH-A26 and SPH-An6, respectively). Peptide lengths from SPH-A26 and SPH-An6 are 402 
between 6 and 26 amino acids.  403 
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Amino acid sequences of fifty low molecular weight peptides from each hydrolysate, 404 
selected based on their easy intestinal absorption, as well as their protein origin, molecular 405 
masses and modifications are presented in Tables 1 and 2. The length of these selected 406 
peptides is between 6 and 10 amino acids. Indeed, it has been reported by Shimizu, Tsunogai, 407 
& Arai (1997) the possibility of the passive diffusion of peptides of more than 4 amino acids, 408 
especially hydrophobic peptides by trancytose. Other transport mecanisms, such as 409 
paracellular diffusion, have been demonstrated for the transport of peptides of more than 4 410 
amino acids (Shimizu, Tsunogai, & Arai, 1997). 411 
The study of the hydrophobicity of selected peptides showed that they are mainly 412 
hydrophobic, which improves their proper effect in the organism. Euston, Finnigan, & Hirst 413 
(2001) reported that the wealth of protein hydrolysates with hydrophobic amino acids 414 
facilitates their digestion and absorption in the intestine and improves their nutritional 415 
properties compared to the intact protein. The most hydrophobic peptides are VIVIIIGA, 416 
ALDILDAA and ILLDLLIP in SPH-A26 and DVILPVPAF, IFAGLIQ, DVPGPVGIPF, 417 
MILPVGAANF in SPH-An6. 418 
By comparing peptides from the two hydrolysates, we found that YELPDGQVI and 419 
FDKIEDMAM are present in both hydrolysates. Moreover, the sequences ISEELDHAL and 420 
SEELDHALN from SPH-A26 and SPH-An6 share the same sequence SEELDHAL. Aspartic 421 
acid (D) and glutamic acid (E) are the main amino acids present in the peptide sequences. 422 
Table 3 reported some peptides sharing sequences with previously identified peptides. 423 
Extended comparison revealed that LEE tripeptide found in the N-terminal sequences of P8 424 
and P20 was also found in LEELEEELEGCE, an antioxidant peptide that was previously 425 
purified from hydrolysate of bullfrog skin, Rana catesbeiana Shaw (Qian, Jung, & Kim, 426 
2008). These three residues are also present in P7, P23 and P24 and could be implicated in the 427 
peptide action. Similarly, the antioxidant peptide (EEEKNRLTKKTKLT) derived from 428 
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bovine milk α-casein (Srinivas & Prakash, 2008) contain KLT at the C-terminal, which is also 429 
present at the C-terminal of VIPELDGKLT (P16), and EEE at the N-terminal, which is also 430 
localized at the N-terminal of EEELEAER (P27). Thus, these peptides could be probably 431 
antioxidant. Furthermore, the three amino acid residues at the N-ter of P22 are also present at 432 
the N-terminal of an antioxidant peptide VGPLSPT (Esteve, Marina, & García, 2015) and the 433 
last three residues are localized at the C-terminal of MDGAP (Esteve, Marina, & García, 434 
2015). These sequences have been reported as antioxidant peptides identified in olive seeds 435 
(Olea europaea). Thus, P22 may have antioxidant activity. Previously, Lee, Cheng, Enomoto, 436 
& Nakano (2006) identified an antioxidant peptide (TDY) from marine bivalve (Mactra 437 
veneriformis) (Liu et al., 2015). This sequence is localized at the C-terminal of P5 which may 438 
be considered as antioxidant peptide.  439 
Potential ACE-inhibitor peptides from SPH-A26 (P4, P13, P18) were also detected, as 440 
these peptides share the same first N-terminal residues of ACE inhibitors previously identified 441 
(Kohmura et al., 1989; Miyoshi, Ishikawa, Kaneko, Fukui, & Tanaka, 1991; Yano, Suzuki, & 442 
Funatsu, 1996; Pihlanto-Leppala, Koskinen, Piilola, Tupasela, & Korhonen, 2000). Further, 443 
P32 contains GQF at the C-terminal, which is also found at the C-terminal of 444 
YIEAVNKVSPRAGQF, an ACE inhibitor peptide from egg yolk (Zambrowicz et al., 2015). 445 
Similarly, the first three residues of P34 (VAP) were previously identified as an ACE 446 
inhibitor peptide (Maruyama, Mitachi, Tanaka, Tomizuka, & Suzuki, 1987). Extended 447 
comparison revealed that sequences of P23, P24 and P25, from SPH-An6, have homology 448 
with LRENNKLMLLELK, a bioactive peptide from bean (Phaseolus vulgaris) (Mojica, 449 
Chen, & de Mejia, 2015), which exihibits antioxidant, ACE and DPP IV-inhibitory activities. 450 
Indeed, the last three residues of this bioactive peptide are localized at the C-terminal of our 451 
peptides and could be implicated in the peptide action. P10 has the same three first residues of 452 
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a dipeptidyl peptidase IV inhibitor, ILAP (Harnedey, O’Keeffe, & FitzGerald, 2015). Thus, 453 
P10 may be hypoglycemic.  454 
 455 
3.5.ACE-inhibitory and antioxidant activities of synthesized peptides 456 
Eight peptides from SPH-A26 and seven peptides from SPH-An6 were selected for 457 
chemical synthesis (Table 4). The selection was based on peptides’ homologies with 458 
previously identified peptides (Biopep data bank) as well as peptides’ length. In fact, it is well 459 
known, that short peptides can be efficiently absorbed through the intestine in an active form, 460 
more readily in comparison to larger peptides (He, Liu, & Ma, 2013). Further, short peptides 461 
generally are more resistant to gastrointestinal digestion and serum peptidases than larger 462 
peptides. 463 
 464 
3.5.1. ACE-inhibitory activity 465 
The ACE-inhibitory activity of synthesized peptides was investigated at a concentration 466 
of 0.25 mM (Fig. 4). The results clearly show that all synthesized peptides displayed ACE-467 
inhibitory activity and P9 (NVPVYEGY) from SPH-A26 exhibited the highest activity 468 
(57.02% ± 0.54), while in SPH-An6, P21 (ITALAPSTM) displayed the highest activity 469 
(52.07% ± 1.88) followed by P31 (SLEAQAEKY) (33.11% ± 2.22). The other peptides 470 
weakly inhibited ACE-activity in vitro.  471 
NVPVYEGY showed IC50 value of 0.21 ± 0.003 mM, while ITALAPSTM and 472 
SLEAQAEKY showed IC50 values of 0.229 ± 0.01 mM and 0.406 ± 0.02 mM, respectively. 473 
The IC50 values of these peptides were higher than that of VIEKYP, an ACE-inhibitor peptide 474 
from mushroom Tricholoma giganteum (IC50= 0.1 µM) (Murray & FitzGerald, 2007) and 475 
KVREGT (IC50= 9.1 µM), a peptide derived from hen ovotransferrin as pro-drug (Lee, 476 
Cheng, Enomoto, & Nakano, 2006). Higher values of IC50 were reported by Pihlanto-Leppala, 477 
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Koskinen, Piilola, Tupasela, & Korhonen (2000) for the fragment of bovine beta-478 
lactoglobulin (VFK) (IC50= 1.029 mM) and by Katayama et al. (2008) who identified an ACE 479 
inhibitor peptide (EKERERQ) from porcine skeletal muscle troponin with an IC50 of 0.552 480 
mM.  481 
The synthesized peptides which exhibited high ACE-inhibitory activity contained a high 482 
content of hydrophobic amino acid residues. Among them, SLEAQAEKY possess a Ser 483 
residue at the N-terminal and Tyr at the C-terminal positions. Although the structure-activity 484 
relation ship of ACE inhibitory peptides has not been fully established, it seems that binding 485 
to ACE is strongly influenced by the C-terminal tripeptide sequence. Indeed, peptides 486 
containing hydrophobic amino acid residues, such as Pro, Phe and Tyr, at the three C-terminal 487 
positions are potent inhibitors (Murray & FitzGerald, 2007). In this respect, the high activity 488 
of QIEDFKEAF could be attributed in particular to Phe at the C-terminal position, one of the 489 
most favourable C-terminal amino acid for binding to the ACE active sites (Gobbetti, 490 
Ferranti, Smacchi, Goffredi, & Addeo, 2000).   491 
 492 
3.5.2.  Antioxidant activities of synthesized peptides 493 
The antioxidant activities of synthesized peptides were also investigated. Fig. 5a shows 494 
the DPPH radical-scavenging activity of synthesized peptides at a concentration of 1 mM. All 495 
peptides were able to scavenge DPPH. The activities of the most active peptides (P1, P5, P6, 496 
P8 and P9 from SPH-A26 and P23 and P33 from SPH-An6) were ranged from 30% to 48%. 497 
Their IC50 values were determined and presented in Table 5. The results indicated that 498 
GTEDELDKY (P33) exhibited the highest radical-scavenging activity (IC50= 1.32 ± 0.01), 499 
followed by NVPVYEGY (P9) (IC50= 1.41 ± 0.03) and AGRDLTDY (P5) (IC50= 1.54 ± 500 
0.01). These IC50 values were lower than that of LEELEEELEGCE (IC50=16.1 mM), an 501 
antioxidant peptide from bullfrog skin hydrolysate (Qian, Jung, & Kim, 2008). On the other 502 
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hand, Liu et al. (2015) identified the peptides TDY and LYEGY with IC50 of 0.14 mM and 503 
0.217, respectively, from an enzymatic hydrolysate of Mactra veneriformis. P21 504 
(ITALAPSTM), which displayed high ACE-inhibitory activity was found to show low DPPH 505 
radical-scavenging activity. The results obtained suggested that some peptides within 506 
sardinelle protein hydrolysates were significantly strong radical scavengers.  507 
Fig. 5b shows the reducing power activities of all synthesized peptides at a concentration 508 
of 0.3 mM compared with BHA as standard. P9 (NVPVYEGY) displayed the highest 509 
reducing power activity, followed by P5 (AGRDLTDY) and P31 (SLEAQAEKY). 510 
The antioxidant activities of synthesized peptides measured by β-carotene bleaching at a 511 
concentration of 1 mM are reported in Fig. 5c and the IC50 values were determined and 512 
presented in Table 5. All synthesized peptides, except P31, showed antioxidant activities. 513 
Results indicate that from SPH-A26, P12 (KDIDDLELT) and P14 (ISEELDHAL) showed the 514 
highest ability to prevent bleaching of β-carotene (IC50= 0.22 ± 0.01 and 0.34 mM ± 0.01, 515 
respectively). From SPH-An6, P19 (EVIEIQ) is the most active peptide (IC50= 0.31 mM ± 516 
0.05).  517 
Moreover, ORAC values of synthesized peptides at a concentration of 0.25 mM are 518 
presented in Fig. 5d. The results indicated that P5, P9, and P14 from SPH-A26 and P21, P29, 519 
P31, and P33 from SPH-An6 displayed high peroxyl radical scavenging activity. Qian, Jung, 520 
& Kim (2008) purified from the hydrolysate of bullfrog skin Rana catesbeiana Shaw an 521 
antioxidant peptide, LEELEEELEGCE. This peptide exhibits peroxyl radical scavenging 522 
activity with an IC50=32.6 mM.  523 
Results showed that P5, P9, and P33, which contain Tyr at their C-terminal displayed 524 
high DPPH radical-scavenging, reducing power and peroxyl radical scavenging activities. The 525 
antioxidant activities of these peptides may result from the Tyr residue localized at C-terminal 526 
position. Furthermore, P14 and P29, which displayed high peroxyl radical scavenging activity 527 
22 
 
contained His in their sequences, and P21, which has Met at the C-terminal, displayed high β-528 
caroten bleaching activity. The presence of His and Met in the sequences of these peptides 529 
could explain their action. In fact, Dávalos, Miguel, Bartolomé, & López-Fandino (2004) 530 
reported that among the amino acids, Trp, Tyr and Met showed the highest antioxidant 531 
activity, followed by Cys, His and Phe. The antioxidant activity of histidine-containing 532 
peptides has been reported and attributed to the chelating and lipid radical-trapping ability of 533 
the imidazole ring (Murase, Nagao, & Terao, 1993; Park, Jung, Nam, Shahidi, & Kim, 2001; 534 
Uchida & Kawakishi, 1992).  535 
 536 
4. Conclusion 537 
In the present study, SPHs obtained by fermentation were found to display antioxidant 538 
and ACE-inhibitory activities. The hydrolysates were analysed using ESI-LC-MS/MS and 539 
peptide sequences were determined. Some of the identified peptides share a partial sequence 540 
homology with previously identified bioactive peptides. Fifteen selected peptides were 541 
synthesized and their ACE-inhibitory and antioxidant activities in vitro were studied. 542 
NVPVYEGY and ITALAPSTM peptides showed the highest ACE inhibitory activity with 543 
IC50 values of 0.21 ± 0.003 and 0.229 ± 0.01 mM, respectively. Regarding the antioxidant 544 
capacity, NVPVYEGY and GTEDELDKY peptides displayed the highest activities. 545 
Therefore, this research provided a scientific basis for the preparation by fermentation 546 
process of antioxidant and hypotensive peptides from sardinelle protein hydrolysates that 547 
could be utilized in food systems as a natural additive possessing antioxidative and preventing 548 
hypertension properties. Further studies will be needed to evaluate the in vivo activities of the 549 
identified peptides. 550 
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Table 1 897 
Selection of peptides identified from SPH-A26 using nESI-LC-MS/MS. 898 
Peptide sequence Protein origin Calculated 
Molecular mass (Da) 
Modifications 
LDDFKL Calcium uniporter protein 749,39  
VIVIIIGA Uncharacterized permease C1683.05  796,54  
ALDILDAA Tegument protein UL47  800,43  
IDFGFDL DNA polymerase  825,39  
ISNIEDF REVERSED Uncharacterized metallohydrolase MJ0457  836,39  
EAPGPINF Myosin regulatory light chain 2 843,41  
LNPTNASH Glycerol-3-phosphate dehydrogenase [NAD(+)]  853,39 Deamidated(N)@2 
GDEGGFAPN Beta-enolase  862,34  
FTIVVAIT REVERSED CASP-like protein F16  862,51  
GFNPPDLD Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  873,39  
AGYDDIQAG Galactose-1-phosphate uridylyltransferase  908,39  
ILLDLLIP ATP-dependent protease ATPase subunit HslU  908,59  
AGRDLTDY Actin, alpha skeletal muscle 909,42  
LIENDEAL Acetylglutamate kinase  915,45 Oxidation(M)@12 
TALEEAEGT Myosin heavy chain, fast skeletal muscle  919,41  
IEEELGDK Enolase  931,45  
IKEAPGPIN Myosin regulatory light chain 2 937,52  
NVPVYEGY Actin, alpha skeletal muscle  939,43  
EAPGPINFT Myosin regulatory light chain 2 944,46  
LEEEVGAAK REVERSED Dihydroxy-acid dehydratase  944,52  
IEEEVKAK Myosin heavy chain, fast skeletal muscle  944,52  
IAAPELEPL Titin  951,53  
NVPIYEGY Actin, alpha skeletal muscle 953,45  
ILAADESTGS Fructose-bisphosphate aldolase A  962,45  
IEFNLVLQ REVERSED Exportin-5  975,53 Deamidated(N)@4 
VFKDLFDP Creatine kinase M-type  979,50  
YETDAIQR Myosin heavy chain, fast skeletal muscle  994,47  
NHDPVVGDR Glycogen phosphorylase, brain form  1007,48  
ADYEDYIK Glycogen phosphorylase, muscle form  1015,45  
GEVEDLMID Myosin heavy chain, fast skeletal muscle  1019,45  
ISEELDHAL Tropomyosin alpha-1 chain  1025,50  
GFEDYVEGL Myosin light chain 1, skeletal muscle isoform  1027,45  
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 899 
 900 
 901 
 902 
 903 
 904 
 905 
 906 
 907 
 908 
 909 
 910 
 911 
 912 
 913 
 914 
YELPDGQVI Actin, alpha skeletal muscle 1032,51  
RVAPEEHPT Actin, alpha skeletal muscle 1034,51  
GTNDETERQ RWD domain-containing protein 2B  1048,44  
KDIDDLELT Myosin heavy chain, fast skeletal muscle  1060,53  
IVDVPVGEEL ATP synthase subunit alpha, mitochondrial  1068,57  
TYDDYVEGL Myosin light chain 3, skeletal muscle isoform  1073,45  
ATEDELDKY Tropomyosin alpha-1 chain  1082,48  
VIPELDGKLT Glyceraldehyde-3-phosphate dehydrogenase  1083,62  
GYPDKIIIGM Beta-enolase  1105,58  
FDKIEDMAM Myosin heavy chain, fast skeletal muscle  1114,47 Oxidation(M)@9 
TIIHLGPRQS Collagen alpha-1(XXVII) chain  1120,63  
ILPDGDHDLK Fructose-bisphosphate aldolase A  1121,57  
GTYDDYVEGL Myosin light chain 3, skeletal muscle isoform  1130,48  
AINDPFIDLD Glyceraldehyde-3-phosphate dehydrogenase, cytosolic  1131,54  
ILENNEALEL Beta-enolase  1157,58 Deamidated(N)@4 
FGYSNRVVDL Glyceraldehyde-3-phosphate dehydrogenase  1169,57166 Deamidated(N)@5 
IDFDEFLKM Troponin C, skeletal muscle  1172,54 Oxidation(M)@9 
TWYDNEFGY Glyceraldehyde-3-phosphate dehydrogenase  1193,47  
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Table 2 915 
Selection of peptides identified from SPH-An6 using LC-MS/MS. 916 
Peptide sequence Protein origin Calculated 
Molecular mass (Da) 
Modifications 
EVIEIQ Citron Rho-interacting kinase  729,39  
IFAGLIQ REVERSED Probable serine/threonine-protein kinase gdt9  760,45  
DELKLF Parvalbumin alpha  763,41  
ELAKTADE REVERSED Serine/arginine-rich splicing factor RS31  875,42  
LEEAGGATAA Myosin heavy chain, fast skeletal muscle  888,42  
ITALAPSTM Actin, alpha skeletal muscle  903,47  
LTALAPSTM Actin-1  903,47  
VGPLGRSGAP REVERSED Collagen alpha-1(VII) chain  909,50  
NASVIPEGQ Myosin heavy chain, fast skeletal muscle  913,45  
DEAGPSIVH Actin, alpha skeletal muscle  923,43  
FIGMESAGI Actin, alpha skeletal muscle  923,44  
FLGMESAGI Actin-2  923,44  
VNDAFGTAH Phosphoglycerate kinase  930,42  
LEEAGGATSV Myosin-7  932,44  
GVDNPGHPF Creatine kinase M-type  938,42  
IIEGDLER Tropomyosin alpha-1 chain  943,50  
LGAHAIHAGL REVERSED Chlorophyll a/b light-harvesting protein PcbC  958,53  
NIIHGSDTL Nucleoside diphosphate kinase B (Fragments)  968,49  
DVILPVPAF Alpha-enolase  969,55  
SELEEELK Tropomyosin alpha-1 chain  975,47  
AGFAGDDAPR Actin, alpha skeletal muscle  975,44  
VLDAGDGVTH Actin, alpha skeletal muscle  982,47  
TQQLEELK Myosin-13  987,52  
DVPGPVGIPF Titin  996,53  
EEELEAER Myosin heavy chain, cardiac muscle isoform (Fragment)  1003,44  
APEEHPTLL Actin, alpha skeletal muscle  1005,51  
SYELPDGQV Actin, alpha skeletal muscle  1006,46  
ASISAFGSNY Lipase  1015,46  
NLTEEMASQ Myosin heavy chain, fast skeletal muscle  1021,44  
SEELDHALN Tropomyosin alpha-1 chain  1026,46  
MILPVGAANF Alpha-enolase  1031,55  
40 
 
 917 
 918 
 919 
 920 
 921 
 922 
 923 
 924 
 925 
 926 
 927 
 928 
 929 
 930 
YELPDGQVI Actin, alpha skeletal muscle  1032,51  
AGLLGTLEEM Myosin-4  1032,52  
SLEAQAEKY Tropomyosin alpha-1 chain  1037,50  
NASVIPEGQF Myosin heavy chain, fast skeletal muscle  1060,52  
TKYETDAIQ Myosin heavy chain, fast skeletal muscle  1067,51  
GTEDELDKY Tropomyosin alpha-1 chain  1068,46  
DLEESTLQH Myosin heavy chain, fast skeletal muscle  1070,49  
ADIAESQVNK Myosin-4  1073,53  
LDKENALDR Tropomyosin alpha-1 chain  1073,53  
AVIDQDKSGF Parvalbumin alpha  1078,53  
DEQSLGAQLQ Myosin heavy chain, fast skeletal muscle  1087,51  
FDKIEDMAM Myosin heavy chain, fast skeletal muscle  1098,47  
VAPEEHPTLL Actin, alpha skeletal muscle  1104,58  
QIEDFKEAF Myosin light chain 3, skeletal muscle isoform  1108,51 Gln->pyro-Glu@N-term 
KEYEPEMGK Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  1109,50  
SYELPDGQVI Actin, alpha skeletal muscle  1119,54  
NFDKVLAEW Myosin heavy chain, fast skeletal muscle  1120,55  
SGFIEEDELK Parvalbumin alpha  1165,55  
SGGTTMYPGIA Actin, alpha skeletal muscle 1053,48  
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Table 3 931 
Comparison of some identified peptides with previously identified bioactive peptides basing 932 
on Biopep data bases. 933 
Hydrolysate  Peptide sequence Previously identified bioactive peptides 
   Sequence Activity Reference 
SPH-A26 P1 LDDFKL GAQCTAGPCCWPCEGTICRR
ARGDDLDDYCNGISADCPRN
PYY    
Antithrombotic  Yeh, Peng, Yih & Huang, 1995 
 
 P2 ALDILDAA KKALRRQEAVDAA   Kinases inhibitor  Ishida et al. 1998 
 P3 IDFGFDL MFDL  
 
ACE inhibitor Murray & FitzGerald, 2007 
 P4 LNPTNASH LNPPHQIYP  
LNP  
LNPA  
 
ACE inhibitor  
ACE inhibitor  
ACE inhibitor  
Kohmura et al. 1989 
Miyoshi, Ishikawa, Kaneko, Fukui & Tanaka, 1991 
Yano, Suzuki & Funatsu, 1996 
 P5 AGRDLTDY TDY  
   
Antioxidant Liu et al. 2015 
 P6 LIENDEAL KKALRRQEALDAL 
TPEVDDEALEK  
 
Kinase inhibitor 
DPP IV inhibitor   
Ishida et al. 1998 
Silveira, Martínez-Maqueda, Recio & Hernández-
Ledesma, 2013 
 P7 TALEEAEGT KVREGT  ACE inhibitor  Lee, Cheng, Enomoto & Nakano, 2006 
 P8 LEEEVGAAK LEELEEELEGCE  Antioxidative Qian, Jung & Kim, 2008 
 P9 NVPVYEGY LYEGY   
LVVDGEGY  
 
Antioxidative 
ACE inhibitor 
Liu et al. 2015 
Esteve, Marina & Garcia, 2015 
 P10 ILAADESTGS ILAP  
 
DPP IV inhibitor Harnedy, O’Keeffe & FitzGerald, 2015 
 P11 IEFNLVLQ GKKVLQ  ACE inhibitor Mito et al. 1996 
 P12 KDIDDLELT LRENNKLMLLELK  Antioxidant,  
ACE inhibitor and  
DPP IV inhibitor   
Mojica, Chen & de Majia, 2015 
 
 P13 VFKDLFDP VFK  
 
ACE inhibitor Pihlanto-Leppala, Koskinen, Piilola, Tupasela & 
Korhonen, 2000  
 P14 ISEELDHAL ISELGW  Antioxidative Tsopmo, Romanowski, Banda, Lavoie & Jenssen, 2011 
 P15 GTNDETERQ EKERERQ  ACE inhibitor  Katayama et al. 2008 
 P16 VIPELDGKLT EEEKNRLTKKTKLT  
 
Antioxidant Srinivas & Prakash, 2008 
 P17 TIIHLGPRQS TIIPLPV  Antioxidative Jiménez-Escrig, Alaiz, Vioque & Rupérez, 2010 
 P18 ILPDGDHDLK ILP  ACE inhibitor  Kohmura et al. 1989 
      
SPH-An6 P19 EVIEIQ LREIQILLRF    Kinase inhibitor Ishida et al. 1998 
 P20 LEEAGGATAA LEELEEELEGCE  Antioxidative Qian, Jung & Kim, 2008 
 P21 ITALAPSTM SALAM  
ALAV  
Antioxidative  
DPP IV inhibitor   
Hernandez-Ledesma, Amigo, Recio & Bartolome, 2007 
Harnedy, O’Keeffe & FitzGerald, 2015 
 P22 VGPLGRSGAP MDGAP; VGPLSPT  Antioxidant Esteve, Marina & García, 2015 
 P23 
P24 
SELEEELK  
TQQLEELK 
LRENNKLMLLELK  Antioxidant,  
ACE inhibitor and  
DPP IV inhibitor 
Mojica, Chen & de Mejia, 2015 
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 934 
 935 
 936 
 937 
 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
 946 
 947 
 948 
 949 
 950 
P25 SGFIEEDELK 
 P26 VLDAGDGVTH VLDTDYK  
                              
VLDTGLAGA  
ACE inhibitor  
            
Antioxidant 
Pihlanto-Leppala, Koskinen, Piilola, Tupasela & 
Korhonen, 2000  
Esteve, Marina & García, 2015 
 P27 EEELEAER 
 
EEE  
EEEKNRLTKKTKLT  
Stimulating 
vasoactive  
Antioxidant 
Ringseis et al. 2005 
Srinivas & Prakash, 2008 
 P28 APEEHPTLL APER  ACE inhibitor  Salampessy, Reddy, Kailasapathy & Phillips, 2015 
 P29 SEELDHALN EELDNALN  Antioxidant Saiga, Tanabe & Nishimura, 2003 
 P30 MILPVGAANF MILMR  
MILLLFR  
Antioxidant 
ACE inhibitor  
Chi et al. 2014 
Toopcham, Roytrakul & Yongsawatdigul, 2015 
 P31 SLEAQAEKY VIEKYP  ACE inhibitor Murray & FitzGerald, 2007 
 P32 NASVIPEGQF YIEAVNKVSPRAGQF  ACE inhibitor Zambrowicz et al. 2015 
 P33 GTEDELDKY SFLLRNPNDKYEPF  Antithrombotic Connolly et al. 1994 
 P34 VAPEEHPTLL VAP  ACE inhibitor  Maruyama, Mitachi, Tanaka, Tomizuka & Suzuki, 1987 
 P35 QIEDFKEAF DWLKAFYDKVAEKLKEAF  Lipids binding Garber et al. 2006 
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Table 4 951 
List of synthesized peptides, molecular weight and purity. 952 
 Synthesized peptide 
sequences 
MW (g moL-1) Purity (%) 
P1 LDDFKL 749.86 99 
P5 AGRDLTDY 909.94 98.1 
P6 LIENDEAL 915.39 99.3 
P8 LEEEVGAAK 945.03 94.6 
P9 NVPVYEGY 940.01 98.7 
P12 KDIDDLELT 1061.15 99.1 
P14 ISEELDHAL 1026.1 98.4 
P15 GTNDETERQ 1049.01 96.5 
P19 EVIEIQ 729.82 98.9 
P21 ITALAPSTM 904.09 97.9 
P23 SELEEELK 976.04 97.7 
P29 SEELDHALN 1027.05 87.6 
P31 SLEAQAEKY 1038.11 99.4 
P33 GTEDELDKY 1069.08 95.5 
P35 QIEDFKEAF 1126.22 86 
 953 
 954 
 955 
 956 
 957 
 958 
 959 
 960 
 961 
 962 
 963 
 964 
 965 
 966 
 967 
 968 
 969 
 970 
 971 
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Table 5 972 
IC50 values of ACE-inhibitory, DPPH free radical scavenging and ß-carotene inhibition 973 
bleaching activities of synthesized peptides identified in SPH-A26 and SPH-An6. 974 
 975 
Peptide ACE-inhibitory 
activity IC50 
(mM) 
Scavenging effect 
on DPPH free 
radical IC50 (mM) 
ß-carotene 
bleaching 
activity IC50 
(mM) 
P1 LDDFKL nd 1.98 ± 0.02b 0.63 ± 0.06c 
P5 AGRDLTDY nd 1.54 ± 0.01d 0.48 ± 0.01d 
P6 LIENDEAL nd 3.38 ± 0.11a nd 
P8 LEEEVGAAK nd 1.64 ± 0.03c 1.03 ± 0.05a 
P9 NVPVYEGY 0.21 ± 0.003c 1.41 ± 0.03d, e 1.11 ± 0.02a 
P12 KDIDDLELT nd nd 0.34 ± 0.01e 
P14 ISEELDHAL nd nd 0.22 ± 0.01f 
P19 EVIEIQ nd nd 0.31 ± 0.05e 
P21 ITALAPSTM 0.229 ± 0.01c nd 0.64 ± 0.001c 
P23 SELEEELK nd 1.67 ± 0.02c 0.99 ± 0.05a 
P31 SLEAQAEKY 0.406 ± 0.02b nd nd 
P33 GTEDELDKY nd 1.32 ± 0.01e 0.82 ± 0.05b 
P35 QIEDFKEAF 0.735 ± 0.02a nd 0.97 ± 0.01a 
 976 
nd: not determined 977 
 978 
 979 
 980 
 981 
 982 
 983 
 984 
 985 
 986 
 987 
 988 
 989 
 990 
 991 
 992 
 993 
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Figure captions 994 
 995 
Fig. 1. ACE-inhibitory activity of sardinelle muscle proteins fermented by B. subtilis A26 996 
(SPH-A26) and B. amyloliquefaciens An6 (SPH-An6) at different concentrations. Values are 997 
means of three independent experiments.  998 
 999 
Fig. 2. Antioxidant activities of sardinelle protein hydrolysates (SPH-A26 and SPH-An6) at 1000 
various concentrations. Scavenging effect on DPPH free radical (a), reducing power (b), ß-1001 
carotene bleaching activity (c), chelating effect (d), oxygen radical absorbance capacity 1002 
(ORAC) (e). Values are means ± SD (n = 3). 1003 
 1004 
Fig. 3. Distribution of peptides identified in SPH-A26 (a) and SPH-An6 (b) by nESI-LC-1005 
MS/MS according to their protein of origin. 1006 
 1007 
Fig. 4. ACE-inhibitory activity of synthesized peptides in SPH-A26 and SPH-An6 at a 1008 
concentration equal to 0.25 mM. The values represent means of three independent 1009 
experiments ± SD. 1010 
 1011 
Fig. 5. Antioxidant activities of synthesized peptides in SPH-A26 and SPH-An6: Scavenging 1012 
effect on DPPH free radical at a concentration equal to 1 mM (a), reducing power at a 1013 
concentration equal to 0.3 mM (b), ß-carotene bleaching activity at a concentration equal to 1 1014 
mM (c), oxygen radical absorbance capacity (ORAC) at a concentration equal to 0.25 mM 1015 
(d). The values represent means of three independent experiments ± SD. 1016 
 1017 
 1018 
 1019 
 1020 
 1021 
 1022 
 1023 
 1024 
 1025 
 1026 
 1027 
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